Comment by European Alzheimer’s Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer’ s disease

Jessen, Frank;Arbizu, Javier;Boada, Mercé;Balasa, Mircea;Bennys, Karim;Boban, Marina;Bürger, Katharina;Chincarini, Andrea;Cagnin, Annachiara;De Deyn, Peter Paul;Düzel, Emrah;Engelborghs, Sebastiaan;Ewers, Michael;Exalto, Lieza G.;van der Flier, Wiesje M.;Fortea, Juan;Frederiksen, Kristian Steen;Frisoni, Giovanni B;Frölich, Lutz;Garza-Martinez, Alejandro J.;Grimmer, Timo;Hanseeuw, Bernard;Hort, Jakub;Ivanoiu, Adrian;Kehoe, Patrick G;Kennelly, Sean P;Kern, Silke;Klöppel, Stefan;Krajčovičová, Lenka;Kramberger, Milica G.;McGuinness, Bernadette;Mecocci, Patrizia;Oberstein, Timo Jan;Ousset, Pierre-Jean;Paquet, Claire;Perneczky, Robert;Piazza, Fabrizio;Plantone, Domenico;Rainero, Innocenzo;Sacco, Guillaume;Salmon, Eric;Santana, Isabel;Scarmeas, Nikolaos;Schneider, Anja;Schott, Jonathan M;Solje, Eino;Stefanova, Elka;Stögmann, Elisabeth;Strauss, Mélanie;Sutovsky, Stanislav;Waldemar, Gunhild;Winblad, Bengt

2025